Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Background: Many patients with locally advanced or metastatic urothelial carcinoma (mUC) need additional treatment options beyond PD-1 PD-L1 inhibitors and platinum-based chemotherapies. Enfortumab vedotin-ejfv (EV) is an antibody–drug conjugate directed at Nectin-4 that received accelerated approval for of adults mUC previously treated PD-1/PD-L1 platinum- containing chemotherapy in the neoadjuvant/adjuvant, advanced, settings. Objectives: This article provides practical considerations recommendations regarding common potentially treatment-limiting adverse events may arise EV therapy. Methods: The clinical data supported are reviewed, supporting safety management provided based on authors’ experience. Findings: therapy can be optimized through patient caregiver education, proactive monitoring, early identification events, timely intervention to alleviate symptoms.